Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Share-based Compensation (2016 - 2026)

Gyre Therapeutics has reported Share-based Compensation over the past 16 years, most recently at $4.6 million for Q4 2025.

  • Quarterly Share-based Compensation rose 710.76% to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2025, up 761.25% year-over-year, with the annual reading at $7.2 million for FY2025, 761.25% up from the prior year.
  • Share-based Compensation was $4.6 million for Q4 2025 at Gyre Therapeutics, up from $1.1 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $12.3 million in Q4 2022 and troughed at $11000.0 in Q1 2024.
  • The 5-year median for Share-based Compensation is $541000.0 (2022), against an average of $1.6 million.
  • Year-over-year, Share-based Compensation tumbled 94.76% in 2024 and then soared 5562.5% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $683000.0 in 2021, then soared by 1698.1% to $12.3 million in 2022, then tumbled by 43.95% to $6.9 million in 2023, then crashed by 91.76% to $567000.0 in 2024, then soared by 710.76% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Share-based Compensation are $4.6 million (Q4 2025), $1.1 million (Q3 2025), and $906000.0 (Q2 2025).